Literature DB >> 23610751

Bone morphogenetic protein in complex cervical spine surgery: A safe biologic adjunct?

Darren R Lebl1.   

Abstract

The advent of recombinant DNA technology has substantially increased the intra-operative utilization of biologic augmentation in spine surgery over the past several years after the Food and Drug Administration approval of the bone morphogenetic protein (BMP) class of molecules for indications in the lumbar spine. Much less is known about the potential benefits and risks of the "off-label" use of BMP in the cervical spine. The history and relevant literature pertaining to the use of the "off-label" implantation of the BMP class of molecules in the anterior or posterior cervical spine are reviewed and discussed. Early prospective studies of BMP-2 implantation in anterior cervical spine constructs showed encouraging results. Later retrospective studies reported potentially "life threatening complications" resulting in a 2007 public health advisory by the FDA. Limited data regarding BMP-7 in anterior cervical surgery was available with one group reporting a 2.4% early (< 30 d) complication rate (brachialgia and dysphagia). BMP use in the decompressed posterior cervical spine may result in neurologic or wound compromise according to several retrospective reports, however, controlled use has been reported to increase fusion rates in select complex and pediatric patients. There were no cases of de novo neoplasia related to BMP implantation in the cervical spine. BMP-2 use in anterior cervical spine surgery has been associated with a high early complication rate. Definitive recommendations for BMP-7 use in anterior cervical spine surgery cannot be made with current clinical data. According to limited reports, select complex patients who are considered "high risk" for pseudoarthrosis undergoing posterior cervical or occipitocervical arthrodesis or children with congenital or traumatic conditions may be candidates for "off-label" use of BMP in the context of appropriate informed decision making. At the present time, there are no high-level clinical studies on the outcomes and complication rates of BMP implantation in the cervical spine.

Entities:  

Keywords:  Bone morphogenetic protein; Cervical spine

Year:  2013        PMID: 23610751      PMCID: PMC3631951          DOI: 10.5312/wjo.v4.i2.53

Source DB:  PubMed          Journal:  World J Orthop        ISSN: 2218-5836


  24 in total

1.  The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report.

Authors:  S D Boden; T A Zdeblick; H S Sandhu; S E Heim
Journal:  Spine (Phila Pa 1976)       Date:  2000-02-01       Impact factor: 3.468

2.  Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine.

Authors:  Joseph D Smucker; John M Rhee; Kern Singh; S Tim Yoon; John G Heller
Journal:  Spine (Phila Pa 1976)       Date:  2006-11-15       Impact factor: 3.468

3.  Occipitocervical fusion in an infant with atlantooccipital dislocation.

Authors:  Edward C Benzel; Donald H Zhang; Christopher Iannotti; Daniel Refai; Paul Ruggieri; Ajit Krishnaney
Journal:  World Neurosurg       Date:  2011-12-24       Impact factor: 2.104

4.  Bone: formation by autoinduction.

Authors:  M R Urist
Journal:  Science       Date:  1965-11-12       Impact factor: 47.728

5.  Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion.

Authors:  Lisa B E Shields; George H Raque; Steven D Glassman; Mitchell Campbell; Todd Vitaz; John Harpring; Christopher B Shields
Journal:  Spine (Phila Pa 1976)       Date:  2006-03-01       Impact factor: 3.468

6.  Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study.

Authors:  Brian Perri; Martin Cooper; Carl Lauryssen; Neel Anand
Journal:  Spine J       Date:  2006-11-20       Impact factor: 4.166

7.  Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis.

Authors:  Charles H Crawford; Leah Y Carreon; Mark D McGinnis; Mitchell J Campbell; Steven D Glassman
Journal:  Spine (Phila Pa 1976)       Date:  2009-06-01       Impact factor: 3.468

8.  Bone morphogenetic protein for salvage fusion in an infant with Down syndrome and craniovertebral instability. Case report.

Authors:  Daniel C Lu; Peter P Sun
Journal:  J Neurosurg       Date:  2007-06       Impact factor: 5.115

9.  Use of osteogenic protein-1 in patients at high risk for spinal pseudarthrosis: a prospective cohort study assessing safety, health-related quality of life, and radiographic fusion. Invited submission from the Joint Section on Disorders of the Spine and Peripheral Nerves, March 2007.

Authors:  Julio C Furlan; Richard G Perrin; Preneshlin V Govender; Yuriy Petrenko; Eric M Massicotte; Yoga R Rampersaud; Stephen Lewis; Michael G Fehlings
Journal:  J Neurosurg Spine       Date:  2007-11

10.  Prospective nonrandomized comparison of an allograft with bone morphogenic protein versus an iliac-crest autograft in anterior cervical discectomy and fusion.

Authors:  Glenn Robin Buttermann
Journal:  Spine J       Date:  2007-03-07       Impact factor: 4.166

View more
  3 in total

1.  Effects of sequentially released BMP-2 and BMP-7 from PELA microcapsule-based scaffolds on the bone regeneration.

Authors:  Xialin Li; Weihong Yi; Anmin Jin; Yang Duan; Shaoxiong Min
Journal:  Am J Transl Res       Date:  2015-08-15       Impact factor: 4.060

2.  Soft tissue swelling incidence using demineralized bone matrix in the outpatient setting.

Authors:  Kingsley R Chin; Fabio J R Pencle; Jason A Seale; Juan M Valdivia
Journal:  World J Orthop       Date:  2017-10-18

3.  Use of Allogenic Mesenchymal Cellular Bone Matrix in Anterior and Posterior Cervical Spinal Fusion: A Case Series of 21 Patients.

Authors:  Srikanth Naga Divi; Mark M Mikhael
Journal:  Asian Spine J       Date:  2017-06-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.